Literature DB >> 20883679

Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC).

Johannes Sander1, Nils Janzen, Michael Terhardt, Stefanie Sander, Gülden Gökcay, Mübeccel Demirkol, Isıl Ozer, Michael Peter, Anibh M Das.   

Abstract

BACKGROUND: Quantification of nitisinone, 2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione (NTBC) has been repeatedly described. Nevertheless monitoring of NTBC has not yet become part of routine therapy surveillance in tyrosinaemia type I (OMIM 276700). We developed a blood spot test to facilitate collection and transport of samples. Furthermore, the test material can be used for determination of other parameters like tyrosine and succinylacetone.
METHOD: For quantification of NTBC in blood spots filter paper discs of 3.2mm diameter were extracted with 150 μL methanol containing mesotrione as internal standard (IS). Analysis was done by UPLC-MS/MS on a Xevo mass spectrometer (ESI+), (MRM). Parent ions were 330.05 for NTBC and 340.05 for IS, daughter ions were m/z 217.95 and m/z 125.95 for NTBC, and m/z 227.95 and m/z 103.95 for IS.
RESULTS: The calibration curve for NTBC in blood spots was linear from 0.1 μmol/L to 100 μmol/L. Recovery exceeded 73.1%, CV intraday and interday were below 9.6%. Instrumental run time was 2.5 min. Sensitivity of the method was 0.1 μmol/L. NTBC concentrations in plasma were higher than in blood spots by a factor of 1.56 ± 0.13.
CONCLUSION: As demonstrated in patients with tyrosinaemia type I quantification of NTBC by UPLC-MS/MS in blood spots is feasible and gives valuable information for monitoring NTBC treatment.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20883679     DOI: 10.1016/j.cca.2010.09.027

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  13 in total

1.  Single dose NTBC-treatment of hereditary tyrosinemia type I.

Authors:  A Schlune; E Thimm; D Herebian; U Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2012-02-04       Impact factor: 4.982

2.  Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria.

Authors:  Ilya Gertsman; Bruce A Barshop; Jan Panyard-Davis; Jon A Gangoiti; William L Nyhan
Journal:  JIMD Rep       Date:  2015-02-10

3.  A Stability Indicating HPLC Method for the Determination of Nitisinone in Capsules.

Authors:  Effat Souri; Farnaz R Lahiji; Tannaz Nourhashemi; H Jalalizadeh
Journal:  Indian J Pharm Sci       Date:  2015 May-Jun       Impact factor: 0.975

4.  A Rapid Screening Test on Dried Blood for the Neonatal Diagnosis of Tyrosinemia Type I.

Authors:  Farahnaz Bodaghkhan; Bita Geramizadeh; Abbas Abdollah Rajeh; Mahmoud Haghighat; Mohsen Dehghani; Naser Honar; Mojgan Zahmatkeshan; Mohammad-Hadi Imanieh
Journal:  Iran J Pediatr       Date:  2016-02-27       Impact factor: 0.364

5.  Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1.

Authors:  Nathalie Guffon; Anders Bröijersén; Ingrid Palmgren; Mattias Rudebeck; Birgitta Olsson
Journal:  JIMD Rep       Date:  2017-06-23

6.  Advantages and Challenges of Dried Blood Spot Analysis by Mass Spectrometry Across the Total Testing Process.

Authors:  Rosita Zakaria; Katrina J Allen; Jennifer J Koplin; Peter Roche; Ronda F Greaves
Journal:  EJIFCC       Date:  2016-12-01

Review 7.  Use of Dried Blood Spot Specimens to Monitor Patients with Inherited Metabolic Disorders.

Authors:  Stuart J Moat; Roanna S George; Rachel S Carling
Journal:  Int J Neonatal Screen       Date:  2020-03-26

8.  Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.

Authors:  Sebene Mayorandan; Uta Meyer; Gülden Gokcay; Nuria Garcia Segarra; Hélène Ogier de Baulny; Francjan van Spronsen; Jiri Zeman; Corinne de Laet; Ute Spiekerkoetter; Eva Thimm; Arianna Maiorana; Carlo Dionisi-Vici; Dorothea Moeslinger; Michaela Brunner-Krainz; Amelie Sophia Lotz-Havla; José Angel Cocho de Juan; Maria Luz Couce Pico; René Santer; Sabine Scholl-Bürgi; Hanna Mandel; Yngve Thomas Bliksrud; Peter Freisinger; Luis Jose Aldamiz-Echevarria; Michel Hochuli; Matthias Gautschi; Jessica Endig; Jens Jordan; Patrick McKiernan; Stefanie Ernst; Susanne Morlot; Arndt Vogel; Johannes Sander; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-08-01       Impact factor: 4.123

Review 9.  Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).

Authors:  Anibh Martin Das
Journal:  Appl Clin Genet       Date:  2017-07-24

10.  Inter-laboratory analytical improvement of succinylacetone and nitisinone quantification from dried blood spot samples.

Authors:  Hilde Laeremans; Charles Turner; Tommy Andersson; Jose Angel Cocho de Juan; Adam Gerrard; M Rebecca Heiner-Fokkema; Diran Herebian; Nils Janzen; Giancarlo la Marca; Mattias Rudebeck
Journal:  JIMD Rep       Date:  2020-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.